Exact Sciences Corp

EXAS

53.940USD

-2.060-3.68%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

12 / 507

Overall Ranking

127 / 4724

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 26 analysts

Buy

Current Rating

64.266

Target Price

+19.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.37% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 65.01.

Overvalued

The company’s latest PE is -9.91, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 202.48M shares, increasing 1.23% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 17.87M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.52.

The company's current financial score is 7.11, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 706.78M, representing a year-over-year increase of 10.86%, while its net profit experienced a year-over-year increase of 8.18%.

Score

Industry at a Glance

Previous score

7.11

Change

0



Financials

7.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.41

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.50

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.19

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.10

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is -8.58, which is 38.68% below the recent high of -11.90 and -407.99% above the recent low of -43.59.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/507

No Data

The company’s current earnings forecast score is 8.59, which is higher than the Biotechnology & Medical Research industry's average of 7.96. The average price target for Exact Sciences Corp is 65.00, with a high of 80.00 and a low of 46.00.

Score

Industry at a Glance

Previous score

8.54

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.98, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 51.25 and the support level at 40.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.06

Change

-0.37

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 106.98%, representing a quarter-over-quarter increase of 0.89%. The largest institutional shareholder is The Vanguard, holding a total of 17.87M shares, representing 9.44% of shares outstanding, with 3.06% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

24.14M

+28.03%

Capital World Investors

17.84M

+1.70%

The Vanguard Group, Inc.

Star Investors

17.56M

+3.64%

Wellington Management Company, LLP

12.50M

+3.67%

BlackRock Institutional Trust Company, N.A.

7.68M

+0.16%

State Street Global Advisors (US)

6.61M

+6.11%

Fidelity Institutional Asset Management

3.59M

+88.60%

T. Rowe Price Associates, Inc.

Star Investors

6.25M

+11.22%

Geode Capital Management, L.L.C.

3.27M

+4.60%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.89, which is higher than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 1.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Exact Sciences Corp

EXAS

6.79 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Protagonist Therapeutics Inc

PTGX

7.04 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.01 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.